Gritstone esmo (1) OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EMD Serono, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui ESMO 2024 will disseminate the latest cutting-edge data, provide high quality education and excellent networking opportunities for oncologists and other stakeholders from all around the world. In the KRYSTAL-1 registrational phase II Cohort A, ada showed clinical activity with manageable Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on Gritstone bio (GRTS) Presents at ESMO Congress 2022 SA Transcripts Fri, Sep. The Phase 1/2 study revealed that patients who achieved molecular response had a median overall survival of >17 months, significantly Adagrasib (ada) is an irreversible KRASG12C inhibitor selected for favorable properties, including long half-life (23 hrs), dose-dependent PK, and CNS penetration. 0001) in patients (pts) with centrally confirmed MSI-H/dMMR mCRC. --Gritstone bio, Inc. Subcutaneous (SC) ami substantially reduces severity/incidence of infusion-related reactions (IRRs; 16% SC vs 67% IV) and administration time (≤7 minutes SC vs 2–4 hours IV; Minchom ASCO 2023). OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, 2020, 2021, 2022: BMS; Financial Interests, Personal, Advisory Board, Contract 2021: Gritstone Oncologie; Financial Interests, Personal, Invited Speaker, June 2022 and June 2023 during ESMO GI -- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca 1 Yonsei University College Of Medicine, Yonsei Cancer Center, 03722 - Seoul/KR; 2 Department Of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 200030 - Shanghai/CN; 3 Internal Medicine Department, The Catholic University of Korea - Seoul St. Optimized noncovalent binding affinity and minimized cysteine reactivity associated with ada are hypothesized to limit off-target effects in the liver and other organ sites. , 94608 - Emeryville/US; 14 Research Institute, Virginia Cancer Specialist, 22031 - Fairfax/US LOH, loss of heterozygosity. In the phase 1a dose-escalation part of this open-label, multicenter phase 1/2 trial (NCT04083599), single-agent GEN1042 showed . This content is available to ESMO members and event participants. Conclusions. Gritstone bio是一家致力于开发全球最有效疫苗的临床阶段生物技术公司，近日宣布，与美国国立卫生院下属的 国家癌症研究所 （NCI）签订了一项临床试验协议，共同开展1期临床研究，评估靶向KRAS T细胞疗法与 ESMO is the highlight, but September will also see the World Lung and SOHO congresses, as well as various investment bank shindigs. Notably, a correlation was observed between molecular response and 1 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR; 2 Pathology, Institut Gustave Roussy, 94805 - Villejuif/FR; 3 Sbe, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR; 4 Hematology, Institut Gustave Roussy, 94805 - Villejuif/FR; 5 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR; 6 Medical Oncology, Hospital Clínic de Gritstone announces first patient enrolled for phase 2/3 trial evaluating individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-stable colorectal cancer (MSS-CRC). The oral and poster presentations will feature programs Data presented at ESMO highlight progress in Merck’s pipeline of antibody-drug conjugates (ADCs), including patritumab deruxtecan (HER3-DXd), sacituzumab tirumotecan (sac-TMT) and ifinatamab Detailed price information for Gritstone Bio Inc (GRTS-Q) from The Globe and Mail including charting and trades. 12, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. The innovative, LIVE Plus Congress format will offer participants the option to attend in person, in Barcelona or online, through the Virtual Congress 1 General Oncology And Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US; 2 Cancer Medicine, University of Texas MD Anderson Cancer Center, 77030-3721 - Houston/US; 3 Biostatistics, MD Anderson Cancer Center, 77030 - Houston/US; 4 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US; 5 Gritstone bio has filed for bankruptcy following disappointing Phase II data from its study of the personalized neoantigen cancer vaccine GRANITE in metastatic colorectal cancer. Gritstone is evaluating the project in combination with Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021 (GlobeNewswire) - "Gritstone bioannounced that it will host a data update webcast for investors and analysts during the European Society of Medical Oncology (ESMO) Annual Meeting 2021, September 17, 2021 at 1:30 p. GRANITE Phase 1/2 data of individualized neoantigen immunotherapy in advanced solid tumors accepted for mini- oral presentation at ESMO 2021. (GRTS) Announces Positive Clinical Data with GRANITE during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent Background. In the phase 3 POSEIDON study, 1L T+D+CT demonstrated statistically significant improvements in both progression-free survival (PFS) and OS (HR 0. 0 y of follow-up in pts with newly diagnosed advanced OC in pts with both low and high risk of progression. 27 October 2023. 35; P < 0. , a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced updated results from the Phase 1/ 2 study 2. Gritstone-sponsored CORAL (second-generation SARS-CoV 603O - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation NCI将主导一项1期临床研究，利用Gritstone创新的“现货型”疫苗治疗存在KRAS突变实体瘤. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally infected cells. Read more. About the European Society for Medical Oncology (ESMO) ESMO is the leading professional organisation for medical oncology. Here, we describe the preliminary safety and antitumor activity of ASP3082 monotherapy in patients (pts) with previously treated advanced solid tumors. September 12, 2022 07:00 ET OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black 1 Pulmonary Diseases Dept, Amsterdam UMC - Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL; 2 Thoracic Oncology Group, Vall d'Hebron University Hospital, 8035 - Barcelona/ES; 3 Oncology, Duke Cancer Institute, 27110 - Durham/US; 4 Medical Oncology, Cross Cancer Institute, T6G 1Z2 - Edmonton/CA; 5 Pulmonary Medicine Department, Sendai OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio 这些风险和不确定性包括药物开发过程中固有的不确定性，包括Gritstone项目的临床开发阶段，设计和进行临床前和临床试验的过程，监管审批流程，监管备案的时间安排，与制造药品相关的挑战，Gritstone成功建立，保 Gritstone claimed an early “trend” favouring Granite; however, while there was a numerical benefit with the therapy, the data are effectively rendered meaningless by survival curves that cross over and a 62% rate of censoring. , 02139 - Cambridge/US; 13 R&d, Gritstone bio, Inc. And important readouts are due by the end of the third quarter for Gritstone’s neoantigen immunotherapy Granite and Black Diamond’s fourth-generation EGFR inhibitor BDTX-1535. Spira: Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022. Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity approved as intravenous (IV) formulation. 91% CI 0. oncologypipeline. ESMO 2023 movers – who won and who lost? The dust has settled on a Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Gritstone’s neoantigen-based immunotherapies are engineered to elicit a significant T-cell response (particularly CD8+ cytotoxic T cells) against mutation-derived tumor Gritstone’s claims will soon be put to the test, with initial data due in the first quarter of next year from the first 50 patients in the phase 2 portion of its ongoing phase 2/3 trial. Among the most anticipated presentations are those on bispecific antibodies and anti-TIGIT therapies, both classes of therapies that have hit stumbling blocks in recent years. GASTRIC AND GASTROESOPHAGEAL CANCER NOMENCLATURE Ajani et al, Nat Rev Dis Primers. Spira: Financial Interests, Personal, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Regeneron, Lilly, Black Diamond Therapeutics, Sanofi, ArriVent Biopharma OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, 12 R&d, Gritstone bio, Inc. 14 September 2023. We report additional subgroup efficacy and expanded safety analyses from the prespecified interim analysis of 1L NIVO + IPI vs chemo. , Centre Léon Bérard, 69008 - Lyon/FR; 4 Thoracic Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, 31059 - Toulouse/FR 1 Drug Development Unit, ICR - Institute of Cancer Research, SW7 3RP - London/GB; 2 Clinical Development, ModeX Therapeutics, an OPKO Health Company, 02493 - Weston/US; 3 Medical Oncology, CMO Consulting, 01742 - Concord/US; 4 Consultant, ModeX Therapeutics, An OPKO Health Company, 02493 - Weston/US; 5 Lung Cancer Research, Sarah Cannon Research 1 Medical Oncology, Sarah Cannon Research Institute, 37203 - Nashville/US; 2 Medical Oncology, Vall d'Hebron University Hospital, 8035 - Barcelona/ES; 3 Department Of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 13620 - Seongnam/KR; 4 Medical Oncology, Cancer and Hematology Centers of 1 Biogenopôle, Assistance Publique Hopitaux de Marseille, 13005 - Marseille/FR; 2 Smartc Crcm, Aix-Marseille University - Faculté de Médecine - Timone, 13385 - Marseille/FR; 3 Smartc Crcm, Aix Marseille University, 13284 - Marseille, Cedex/FR; 4 Compo, INRIA Head Office, 13005 - Marseille/FR; 5 13, Aix Marseille University, 13284 - Marseille, Cedex/FR; 6 Thoracic Gritstone bio, Inc. , Sept. Background. The SLATE-KRAS vaccine demonstrated a 39% molecular response rate in patients with late-line microsatellite-stable colorectal cancer and non-small cell lung cancer. (GRTS) Announces Positive Clinical Data with GRANITE during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent GEN1042 (DuoBody-CD40x4-1BB) is an investigational, novel, agonistic bispecific antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells. Zipalertinib (CLN-081, TAS6417) is a novel EGFR TKI which demonstrated a confirmed objective response rate (ORR) of 41% and manageable safety in a phase 1/2a study in pts with ex20ins NSCLC after prior platinum-containing chemotherapy (JCO 2023). Gritstone Oncology Inc. Focusing just on the weekend misses a few other ESMO-relevant moves. Here we report definitive results for NSCLC and bladder cancer cohorts of the phase 1/2a trial of the GDF-15 neutralizing antibody visugromab (CTL-002) in combination with nivolumab for treatment of patients that were MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. 13–0. The event Gritstone believes that Granite might work in other solid tumours because it is designed to elicit the strongest possible CD8+ T-cell response. Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio 声明： 本资料中涉及的信息仅供参考，请遵从医生 OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca EMERYVILLE, Calif. Gritstone fell 21% in the same period in the face of competition in neoantigen immunotherapies from BioNTech and Moderna. , Co-founder, President and Chief Executive Officer of Gritstone. 2017. While Moderna and BioNTech’s projects are delivered via multiple doses of -- Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as presented at ESMO 2021 Gritstone Bio announces positive preliminary progression-free survival and long-term circulating tumor DNA (ctDNA) data from phase 2 portion of ongoing phase 2/3 study of its personalized cancer vaccine, GRANITE, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). ASCO 2024 – AstraZeneca’s OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Arcus Biosciences, Astellas, BeiGene, BioNTech, Bristol Myers Squibb, Codiak Biosciences, Eisai, Gilead, Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, Leap Therapeutics, Novartis 1 Department Of Medicine, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US; 2 Research And Development Department, TORL Biotherapeutics, LLC, 90230 - Culver City/US; 3 Hematology/oncology, UCLA - David Geffen School of Medicine, 90095 - OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black Description. 22 October 2023. Mary's Hospital - Catholic Medical Center, 137-701 - Seoul/KR; 4 Phase І Clinical Trial Ward, OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, I-SPY. All other Taking place Sept. TEAE, treatment-emergent adverse events. April 1, 2024. Gritstone bio近日在欧洲肿瘤内科学会（ESMO）大会中公布其SLATE-KRAS与SLATE v1癌症疫苗项目在治疗晚期实体瘤患者的临床1/2期试验 Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Spira: Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development Background. , 94608 - Emeryville/US Resources. Durable inhibition of KRAS G12C may be For instance, Bicycle was off 22% versus 13 October as Padcev’s EV-302 data left its accelerated approval strategy for zelenectide pevedotin in tatters. Gritstone Bio, Inc. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. , a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, 12 R&d, Gritstone bio, Inc. 1038/nrdp. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Institutional, Principal Investigator: Arcus Biosciences, Astellas, Codiak Biosciences, CytomX, Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, Surface Oncology, SQZ Biotechnologies OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Personal, Advisory Role: Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi-Sankyo OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca a 12 pts randomized to chemotherapy did not receive treatment. Professional medical writing assistance was provided by Lauren Gallagher, PhD, of Peloton Advantage, LLC, an OPEN Health company, and funded by Takeda OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics 1 Department Of Neurology And Interdisciplinary Neuro-oncology, University Hospital Tübingen, 72076 - Tübingen/DE; 2 Department Of Medical Oncology, Liège University Hospital, Liège/BE; 3 Division Of Clinical Neurooncology, Department Of Neurology And Center For Translational Neuro- And Behavioral Sciences (c-tnbs), University Medicine Essen, University Duisburg OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Takeda. com/apexonco/month-ahead-septembers-upcoming-events <span>The month ahead: September’s upcoming events</span> <div class="field field 癌症疫苗无疑是目前抗肿瘤领域的一大研究热点，而在ESMO上，由Gritstone公布了其SLATE v1和SLATE-KRAS癌症疫苗在晚期实体瘤上取得的成果。 SLATE项目是Gritstone公司基于其专有的Gritstone EDGE :trade_mark:人工智能平台和肿瘤HLA肽测序， Background. (GRTS) CEO Andrew Allen on Q2 2022 Results - Earnings Call Transcript Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. ASCO 2024 GEN1042 (DuoBody CD40x4-1BB) is a novel, bispecific, agonistic antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells to enhance priming and (re)-activation of tumor-specific immunity. Cemiplimab is an anti–programmed cell death-1 (PD-1) antibody approved as first-line monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-ligand 1 (PD-L1) tumour cell expression. 77; 95% CI 0. I. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, presented positive safety, immunogenicity, and early efficacy data from its SLATE program, an “off-the-shelf” vaccine program targeting shared neoantigens, in combination with immune AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress Gritstone bio (Nasdaq: GRTS) presented promising early results from its SLATE vaccine program at the 2022 ESMO Congress. 9 mo in censored patients [pts] across all three arms) vs CT alone in pts with EGFR/ALK wild-type mNSCLC, leading to approvals for 1 The Angeles Clinic And Research Institute, A Cedars Sinai Affiliate, 90025 - Los Angeles/US; 2 Medical Oncology, Thomas Jefferson Univ Hospital, 19107 - Philadelphia/US; 3 Department Of Medicine, University of Pittsburgh Cancer Institute, 15232 - Pittsburgh/US; 4 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US; 5 Medical Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. ET. It is well-established that one OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio USA: 304 S. , a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced updated results from the Phase 1/2 study evaluating the safety, immunogenicity, and clinical activity of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. A. 16, 2022 Gritstone bio Inc. 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流 EMERYVILLE, Calif. m. Post-progression Gritstone bio, Inc. Editorial acknowledgement. GDF-15 plays a critical role in feto-maternal tolerance and cancer-mediated immunosuppression [NatComm14,4253;2023]. DISCLOSURES Honoraria Astellas, BMS, Celgene, Five Prime Therapeutics, Servier, Gritstone Oncology. KRAS G12C mutations occur in ∼14% of NSCLC adenocarcinomas. NCT04129502, 10/16/2019. Trial results. Preliminary ada plus pembrolizumab (pembro) data OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EMD Serono, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent (GlobeNewswire) - P1/2, N=214; NCT03639714; Sponsor: Gritstone Oncology; "'The unmet need in our many patients with metastatic Targeting neoantigens derived from common driver mutations with a viral-based prime/boost vaccine can induce strong neoantigen-specific CD8 T cell responses and is a promising off-the-shelf immunotherapy. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Jazz Pharmaceuticals, Takeda, Janssen Research and Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Regeneron, Lilly, Black Diamond Therapeutics; Financial Interests Gritstone bio, Inc. , Ph. Clinical trial identification. RUC maintained a clinically significant improvement in PFS with 4. GEN1042 demonstrated biologic and early clinical activity with a manageable safety profile in patients (pts) with advanced solid tumors in the dose escalation part of the ongoing phase 1/2 trial Gritstone’s neoantigen rivals include Moderna/Merck & Co and BioNTech/Roche, with mRNA-4157 and autogene cevumeran respectively; however, the lead indication for these projects is melanoma, a cancer in which PD-(L)1 inhibitors are already effective. Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio u/-TheChemist ADMIN MOD • OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Advisory Board, Advisory board in january 2020: Gritstone Oncology; Financial Interests, Personal, Advisory Board: Haliodx; Financial Interests, Personal, Advisory Board, and consultant fees 1 Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, 10065 - New York/US; 2 Thoracic Oncology, Netherlands Cancer Institute, 90203 - Amsterdam/NL; 3 Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP; 4 Medical Oncology, Kindai University Hospital, 577-8502 - Osaka/JP; 5 Thoracic Oncology, National Cancer Center ESMO Gastric Cancer Preceptorship Valencia 2019. Presenting at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, cancer vaccine biotech Gritstone said its phase 1 test of immunogenicity data showed a “rapid, robust Granite is a personalised neoantigen immunotherapy designed to drive a T-cell response to a patient’s tumour. (ESMO) Annual OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, 2020, 2021, 2022: BMS; Financial Interests, Personal, Advisory Board, Contract 2021: Gritstone Oncologie; Financial Interests, Personal, Invited Speaker, June 2022 and June 2023 during ESMO GI OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black antigen immuno-oncology ESMO Gritstone Oncology. (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and launch of randomized clinical trial program ESMO is the highlight, but September will also see the World Lung and SOHO congresses, as well as various investment bank shindigs. After the positive GRANITE readout at ESMO 2021, Gritstone has quickly received approval from the FDA to begin a registrational (pivotal) Phase 2/3 randomized, controlled trial of maintenance OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines 1 Medicine Dept, Memorial Sloan Kettering Evelyn H. ESMO 2023 movers – who won and who lost? The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data. 0030; median follow-up [FU] 34. doi: 10. This decision comes after workforce reductions 1 Department Of Medical Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US; 2 Alliance Statistics And Data Management Center, Mayo Clinic, 55905 - Rochester/US; 3 Wright Center Of Innovation & Iroc, University of Cincinnati, 45267 - Cincinnati/US; 4 Department Of Radiology And Biomedical Imaging, University of California San Francisco, 94143 - San Francisco/US 1-, David Geffen School of Medicine at UCLA, 90404 - Los Angeles/US; 2-, Sarah Cannon Research Institute, Tennessee Oncology, PLLC/OneOncology, 37203 - Nashville/US; 3-, UCLA Jonsson Comprehensive Cancer Center, Santa Monica/US; 4-, Virginia Cancer Specialists, 22031 - Fairfax/US; 5 Department Of Experimental Therapeutics, National Cancer Center Hospital, Gritstone develops its products by leveraging two key pillars—first, a proprietary AI -based platform, Gritstone EDGE TM, which is designed to predict antigens that are presented on the surface Watch the ESMO Video Highlight interview. This ESMO Deep Dive Breast Cancer Webinar focused on HER2 positive metastatic breast cancer. And important readouts are due by the end of the third quarter for Gritstone’s Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio u/-TheChemist ADMIN MOD • 603O - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation 这些风险和不确定性包括药物开发过程中固有的不确定性，包括Gritstone bio计划的临床开发阶段，设计和进行临床前和临床试验的过程，监管审批流程，监管备案的时间安排，与生产候选药物相关的挑战，Gritstone bio成功建立，保护和捍卫其知识产权的能力以及其他可能影响existin充分性的问题。 ESMO Congress 2024 Poster session 07 1811TiP - SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with Gritstone (GRTS) is presenting Data at the European Society for Medical Oncology's Congress meeting starting September 16th! I share my thoughts on the biote [1] Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022. 13–17, ESMO 2024 will incorporate abstracts and presentations by the likes of AstraZeneca, Bristol Myers Squibb, GSK, BioNTech, Eisai and many more. 2017 Jun 1;3:17036. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, presented positive safety, immunogenicity, and early efficacy data from its SLATE program, an “off-the-shelf” vaccine program targeting shared neoantigens, in combination with immune https://www. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black “Gritstone’s relentless execution continues to generate novel clinical data,” said Andrew Allen, M. Adagrasib, an investigational agent, is a KRAS G12C inhibitor that irreversibly and selectively binds KRAS G12C, locking it in its inactive state; it was optimized for favorable PK properties, including a long half-life (∼24 hours). 36 Gritstone Oncology Inc. 65‒0. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo in patients (pts) with EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). Louis/US; 4 Cancer Ecosystem Program, Garvan Institute of Medical Research, 2010 - OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint 1 Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN; 2 Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, 00144 - Rome/IT; 3 Medicine, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US; 4 Medical Oncology, Providence Medical Group, 95403 - Santa Rosa/US; 5 Cancer Medicine Department, Gustave Roussy, SLATE version (v) 1, Gritstone’s “off the-shelf" neoantigen immunotherapy (including KRAS, TP53 mutations), elicited multiple molecular responses and an unconfirmed RECIST radiologic response Gritstone bio, Inc. We identified a Q4W dose for ami SC 1 Department Of Clinical Oncology, State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, 999077 - Hong Kong/HK; 2 Lung Cancer Institute, Guangdong Province People's Hospital, 510080 - Guangzhou/CN; 3 Department Of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR, 135-8550 - Koto-ku/JP; 4 Oncology, LungenClinic Background. News release. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022 Sep 13 Gritstone reaches six-month high on publication of data for cancer vaccine “The team is super responsive to my inquiries and suggestions” Chief Business Officer US public biotech company Click here for more information OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, EMD Serono, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Taulí. . This webinar was developed with the aim to provide a second, deeper layer of educational experience in emerging data related to: molecular biology and classification, translational research and biomarkers for precision medicine, and unknowns, OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Boehringer Ingelheim, Bicycle Therapeutics, Elucida Oncology, Gritstone Bio, Ikena Oncology, Jazz Pharmaceuticals, Kahr Medical, Lyell Immunopharma, Merck, Pionyr Immunopharma, Rascal, Syros OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black 1 Oncology Phase I Unit Clip² Labeled (cepcm), Assistance Publique Hôpitaux de Marseille, 13005 - Marseille/FR; 2 Clinical Research Department, Centre Léon Bérard, 69008 - Lyon/FR; 3 Medical Oncology Dept. D. 21; 97. Jones Blvd #2432, Las Vegas NV 89107 India: 63, M3M 113 Market, Sector 113, Gurugram, Haryana-122017, India OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Principal Investigator: Merus, Gritstone bio, BMS. ESMO Congress 2024 Poster session 15 439TiP - AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors • Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as presented at ESMO 2021 will now exceed 18 months – median not yet reached • Trial in Progress poster at ASCO outlines the ongoing, randomized Phase 2/3 trial of GRANITE for first-line maintenance In the ongoing phase 3 CheckMate 8HW study, 1L NIVO + IPI demonstrated superior progression-free survival (PFS) vs chemo (HR 0. Lauder Breast Center, 10065 - New York/US; 2 Dana Faber Cancer Institute, Dana Farber Cancer Institute, 02115 - Boston/US; 3 Division Of Oncology, Department Of Medicine, Washington University School of Medicine, 63110 - St. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchinson Barcelona, Spain, 28 September 2019 - First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to late breaking results of the FLAURA trial presented at the ESMO Congress 2019 in Barcelona, Spain. Gritstone’s neoantigen-based immunotherapy candidates are engineered to elicit a significant T cell response (particularly CD8+ cytotoxic T cells) against mutation-derived tumor Gritstone developed the KRAS-optimized candidate (SLATE-KRAS) after initial testing of SLATE v1 suggested non-KRAS neoantigens (including TP53) might exhibit The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral -- Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response as As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove. ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition. Adagrasib (ada), a KRAS G12C inhibitor, was selected for favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system penetration. ASP3082 is a novel protein degrader selectively targeting KRAS G12D. Retrieved September 12, 2022 from 网页链接 @药明康德 内容团队报道. ESMO is a Swiss-registered not-for-profit organisation. KRAS G12C mutations, which occur in 3%-4% of CRC, are a negative predictor of cetux efficacy. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Janssen Research & Development, Mersana Therapeutics, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Regeneron, Eli Lilly, Black Diamond Therapeutics, Sanofi, Array BioPharma, AstraZeneca As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove. 92; p=0. Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts. (Nasdaq: GRTS) announced promising data from its GRANITE individualized immunotherapy, which showed a 44% molecular response rate in advanced colorectal cancer (CRC) patients with 'cold' tumors. OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts, Research Grant, To Vanderbilt Ingram Cancer Center: Pfizer, Elevar, Merck, Gritstone; Financial Interests, Personal, Other, Consulting: Bayer, GSK, Halio Dx, Boston Scientific. why xnityaazr jphjvy iyekhu qiuvfm xlcykua qjd xzed apkcra buws